Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $20.88 Consensus PT from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $20.88.

Several brokerages have weighed in on TEVA. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Barclays raised their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Finally, StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th.

Teva Pharmaceutical Industries Stock Up 4.4 %

NYSE:TEVA opened at $21.90 on Monday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The company’s fifty day moving average price is $19.06 and its 200-day moving average price is $18.14. Teva Pharmaceutical Industries has a 1-year low of $10.83 and a 1-year high of $22.80. The firm has a market capitalization of $24.81 billion, a P/E ratio of -25.76, a PEG ratio of 0.99 and a beta of 0.73.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently bought and sold shares of the company. UMB Bank n.a. lifted its position in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after acquiring an additional 2,067 shares in the last quarter. Smithfield Trust Co lifted its holdings in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $50,000. Claro Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth $52,000. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $60,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.